“Biote’s third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to growth in our dietary supplements business,” said ...

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

Peterson stated, "we reiterate our fiscal 2025 revenue guidance of above $190 million and our fiscal 2025 adjusted EBITDA guidance of above $50 million." Management continues to expect mid-teens ...

Reports Q3 revenue $51.4M, consensus $51.4M. “Biote’s (BTMD) third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to ...

Reports Q4 revenue $49.8M, consensus $51.2M. “In 2024 Biote (BTMD) strengthened its capabilities to provide the next level of individualized and evidence-based healthcare,” said Bob Peterson, Biote ...

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

biote Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Biote First Quarter 2024 Earnings ...